The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 26, 2007

Filed:

Aug. 07, 2003
Applicants:

Nilgun E. Tumer, Belle Mead, NJ (US);

Jonathan D. Dinman, North Brunswick, NJ (US);

Katalin A. Hudak, East Brunswick, NJ (US);

Inventors:

Nilgun E. Tumer, Belle Mead, NJ (US);

Jonathan D. Dinman, North Brunswick, NJ (US);

Katalin A. Hudak, East Brunswick, NJ (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/82 (2006.01); C12N 5/04 (2006.01); C12N 1/20 (2006.01); C12N 15/81 (2006.01); C12N 15/70 (2006.01); C07H 21/04 (2006.01); A01H 5/10 (2006.01);
U.S. Cl.
CPC ...
Abstract

Disclosed are transgenic plants containing an exogenous nucleic acid encoding an L3 protein. The plant exhibits increased resistance to viruses and/or fungi that infect plants. The L3 proteins include wild-type proteins, spontaneously occurring mutants and non-naturally occurring L3 mutants. Also disclosed are methods of reducing the toxicity of single-chain ribosome inhibitory proteins in cells, e.g., yeast, plant and animal cells, by co-administering the L3 protein with the RIP. Further disclosed are non-naturally occurring L3 mutants that (a) substantially fail to bind single-chain RIPs that bind endogenous L3 proteins, (b) are unable to maintain M1 killer virus, (c) promote altered programmed ribosomal frameshift efficiency, (d) exhibit resistance to peptidyltransferase inhibitors, and combinations of any of (a)–(d).


Find Patent Forward Citations

Loading…